Secondary Varicose Small Pelvic Veins and Their Treatment with Micronized Purified Flavonoid Fraction

Abstract

The aim of this study was to examine secondary varicose small pelvic veins (VSPV) and their treatment with micronized purified flavonoid fraction (MPFF). We examined 70 patients with a history of acute iliac thrombosis of > 1 year. Patients with urination difficulties associated with other symptoms (n = 24) received MPFF 1,000 mg once daily for 1 month. Clinical manifestations were assessed by collecting complaints and analyzing results of physician examinations. VSPV was identified in 48 (68.6%) patients, the majority (58%) had grade 2 (7.0–9.0 mm) venous dilation. VSPV severity correlated with time since the thrombotic event. In most women, varicosities were found in the parametrial venous plexus (mean vein diameter 7.91 mm); retrograde flow during the Valsalva maneuver was found in 14 (78%). In men, all varicosities occurred in the paraprostatic plexus (mean vein diameter 7.20 mm); retrograde flow was found in 21 (70%). MPFF significantly reduced VSPV dilation in 18 (75%) patients (p = 0.0863) and returned ultrasonic indices to normal values in the remainder. Patients with bilateral varices decreased from 10 to 2. Only four patients had retrograde flow in the SPV plexus after treatment. MPFF decreased mean paraprostatic vein diameter in men and parametrial vein diameter in women to near-normal values. Clinical improvement was reported in 13 (54%) patients. Patients with pelvic pain decreased from 8 to 1 and patients with urination disorders from 24 to 9. VSPV is common in patients with a history of iliac vein thrombosis. MPFF decreases the diameter of affected veins, improves retrograde flow and pelvic hemodynamics, and significantly reduces the severity of the clinical manifestations.

Keywords

iliac vein thrombosis - micronized purified flavonoid fraction - retrograde flow - varicose small pelvic veins - secondary varicose

• References

• 1 Crisostomo PR, Cho J, Feliciano B, Klein J, Jones D, Dalsing MC. Period frequency of iliofemoral venous occlusive disease by Doppler ultrasound and corresponding treatment in a tertiary care facility. J Vasc Surg 2010; 52 (5) 1272-1277
• 2 Pollack Jr CV. Advanced management of acute iliofemoral deep venous thrombosis: emergency department and beyond. Ann Emerg Med 2011; 57 (6) 590-599
• 3 Casey ET, Murad MH, Zumaeta-Garcia M , et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg 2012; 55 (5) 1463-1473
• 4 Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. Rev Cardiovasc Med 2002; 3 (Suppl. 02) S61-S67
• 5 Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008; 25 (1) 37-44
• 6 Holzheimer RG. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res 2004; 9 (4) 225-239
• 7 Wong YM, Quek YN, Tay JC, Chadachan V, Lee HK. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration. J Clin Pharm Ther 2011; 36 (5) 585-591
• 8 Taylor Jr HC. Vascular congestion and hyperemia; their effect on function and structure in the female reproductive organs; etiology and therapy. Am J Obstet Gynecol 1949; 57 (4) 654-668
• 9 Hobbs JT. The pelvic congestion syndrome. Br J Hosp Med 1990; 43 (3) 200-206
• 10 Fernández-Samos R, Zorita A, Ortega JM , et al. Female gonadal venous insufficiency [in Spanish]. Angiologia 1993; 45 (6) 203-209
• 11 Liddle AD, Davies AH. Pelvic congestion syndrome: chronic pelvic pain caused by ovarian and internal iliac varices. Phlebology 2007; 22 (3) 100-104
• 12 Tsukanov A. Varicose disease of the pelvis as the cause of LUTS in men. J Men's Health 2011; 8 (3) 208
• 13 Pascarella L. Essentials of Daflon 500 mg: from early valve protection to long-term benefits in the management of chronic venous disease. Curr Pharmaceutic Des 2007; 13 (4) 431-444
• 14 Nicolaides AN. From symptoms to leg edema: efficacy of Daflon 500 mg. Angiology 2003; 54 (Suppl. 01) S33-S44
• 15 Ramelet AA. Daflon 500 mg: symptoms and edema clinical update. Angiology 2005; 56 (Suppl. 01) S25-S32
• 16 Goldman MP, Guex JJ, Weiss RA. Sclerotherapy Treatment of Varicose and Telangiectatic Leg Veins. 5th ed. London: Elsevier Saunders; 2011: 401
• 17 Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011; 41 (1) 117-125
• 18 Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol 2005; 3 (1) 1-9
• 19 Burak F, Gonduz T, Simsek M, Taskin O. Chronic pelvic pain associated with pelvic congestion syndrome and the benefit of Daflon 500 mg: a review. Phlebolymphology 2009; 16 (3) 290-294
• 20 Venbrux AC, Chang AH, Kim HS , et al. Pelvic congestion syndrome (pelvic venous incompetence): impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. J Vasc Interv Radiol 2002; 13 (2 Pt 1): 171-178
• 21 Belardi P, Viacava A, Lucertini G. Iliac vein insufficiency syndrome. Clinical contribution [in Italian]. Minerva Cardioangiol 1998; 46 (6) 211-214
• 22 Bergan JJ. Treatment of pelvic venous reflux (pelvic venous congestion) in North America. Vasc Surg 1997; 31 (3) 255-261
• 23 Koo S, Fan CM. Pelvic congestion syndrome and pelvic varicosities. Tech Vasc Interv Radiol 2014; 17 (2) 90-95